BACKGROUND The trend toward late childbearing has made fertility preservation a major issue for women who face gynecological cancer. New techniques in assisted reproductive medicine enable conception after primary treatment of these cancers. Here, we aimed to review the efficacy and safety of assisted reproductive techniques (ART) after fertility-preserving treatment of gynaecological cancers. METHODS We conducted a systematic literature review of both prospective and retrospective studies in the PubMed, EMBASE, CENTRAL and SciSearch databases. In the retrieved studies, we evaluated live births, clinical pregnancies, overall survival and disease-free survival. RESULTS We identified many prospective and retrospective studies on this topic, but no relevant randomized clinical trials. Fertility-sparing treatments with safe oncological outcomes are feasible in endometrial, cervical and ovarian cancer cases. After cancer treatment, ART seem safe and show variable obstetrical outcomes. CONCLUSIONS After fertility-preserving treatment for gynaecological cancers, ART can enable pregnancy to be achieved with apparent oncological safety. The success of such procedures should directly impact clinical practice and management of those patients who require fertility-sparing treatment.

中文翻译：

---

保留生育能力的妇科癌症治疗后的辅助生殖技术。

背景技术晚期生育的趋势已使保持生育力成为面对妇科癌症的妇女的主要问题。辅助生殖医学的新技术使这些癌症的初步治疗成为可能。在这里，我们旨在回顾保留生殖力的妇科癌症治疗后辅助生殖技术（ART）的功效和安全性。方法我们对PubMed，EMBASE，CENTRAL和SciSearch数据库中的前瞻性研究和回顾性研究进行了系统的文献综述。在检索的研究中，我们评估了活产，临床妊娠，总生存期和无病生存期。结果我们确定了关于该主题的许多前瞻性和回顾性研究，但没有相关的随机临床试验。在子宫内膜癌，宫颈癌和卵巢癌病例中，可行的具有安全肿瘤学结局的治疗方法是可行的。经过癌症治疗后，抗逆转录病毒疗法似乎是安全的，并显示出可变的产科结局。结论保留生育力的妇科癌症治疗后，抗逆转录病毒疗法可使妊娠得以实现，并具有明显的肿瘤学安全性。此类程序的成功应直接影响那些需要节育治疗的患者的临床实践和管理。